Skip to main content
icon for Wird AbbVie Q2 Global Skyrizi Nettoumsatz über __ liegen?
Finanzen·ABBV

Wird AbbVie Q2 Global Skyrizi Nettoumsatz über __ liegen?

icon for Wird AbbVie Q2 Global Skyrizi Nettoumsatz über __ liegen?
Finanzen·ABBV

Wird AbbVie Q2 Global Skyrizi Nettoumsatz über __ liegen?

Juli 31

Juli 31

Juli 31

Juli 31

NEU
31. Juli 2026
Polymarket

$768 Vol.

Polymarket

18 Mrd. $

$65 Vol.

28%

19 Mrd. $

$65 Vol.

25%

20 Mrd. $

$67 Vol.

12%

21 Mrd. $

$0 Vol.

45%

22 Mrd. $

$571 Vol.

23%

This market will resolve to "Yes" if AbbVie's Global Skyrizi net revenues for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No". The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered. If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No". If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to "No". If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market. The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used. Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.AbbVie’s Skyrizi continues to drive immunology revenue growth amid ongoing Humira erosion, with Q1 2026 global net sales reaching $4.483 billion, up 30.9% year-over-year on strong uptake across psoriasis, psoriatic arthritis, and Crohn’s indications. Sequential momentum, new label expansions, and competitive positioning versus other IL-23 and JAK inhibitors shape trader views ahead of the July 31 earnings release, when Q2 results and any updated full-year guidance will be disclosed. Analysts project sustained double-digit expansion consistent with the product’s recent trajectory and the company’s raised 2026 EPS range of $14.08–$14.28. Market-implied odds embed these fundamentals while accounting for potential variability in U.S. pricing dynamics and volume trends.

This market will resolve to "Yes" if AbbVie's Global Skyrizi net revenues for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No".

The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.

If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No".

If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to "No".

If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.

The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.

Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
Volumen
$768
Enddatum
31. Juli 2026
Markt eröffnet
Jul 18, 2026, 4:41 PM ET

Resolver

0x65070BE91...
This market will resolve to "Yes" if AbbVie's Global Skyrizi net revenues for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No". The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered. If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No". If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to "No". If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market. The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used. Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
This market will resolve to "Yes" if AbbVie's Global Skyrizi net revenues for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No". The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered. If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No". If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to "No". If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market. The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used. Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.AbbVie’s Skyrizi continues to drive immunology revenue growth amid ongoing Humira erosion, with Q1 2026 global net sales reaching $4.483 billion, up 30.9% year-over-year on strong uptake across psoriasis, psoriatic arthritis, and Crohn’s indications. Sequential momentum, new label expansions, and competitive positioning versus other IL-23 and JAK inhibitors shape trader views ahead of the July 31 earnings release, when Q2 results and any updated full-year guidance will be disclosed. Analysts project sustained double-digit expansion consistent with the product’s recent trajectory and the company’s raised 2026 EPS range of $14.08–$14.28. Market-implied odds embed these fundamentals while accounting for potential variability in U.S. pricing dynamics and volume trends.

This market will resolve to "Yes" if AbbVie's Global Skyrizi net revenues for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No".

The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.

If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No".

If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to "No".

If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.

The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.

Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
Volumen
$768
Enddatum
31. Juli 2026
Markt eröffnet
Jul 18, 2026, 4:41 PM ET

Resolver

0x65070BE91...
This market will resolve to "Yes" if AbbVie's Global Skyrizi net revenues for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No". The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered. If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No". If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to "No". If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market. The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used. Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.

Verwandte

icon for Werden die globalen Nettoumsätze von Rinvoq von AbbVie im zweiten Quartal über 2,3 Milliarden US-Dollar liegen?

Werden die globalen Nettoumsätze von Rinvoq von AbbVie im zweiten Quartal über 2,3 Milliarden US-Dollar liegen?

80%
Ja
icon for Werden die Q2-Rating-Umsätze von S&P Global (SPGI) über 12,5 Mrd. $ liegen?

Werden die Q2-Rating-Umsätze von S&P Global (SPGI) über 12,5 Mrd. $ liegen?

3%
Ja
icon for Will Verizon (VZ) Q2 total operating revenue be above $34.5B?

Will Verizon (VZ) Q2 total operating revenue be above $34.5B?

86%

Vorsicht bei externen Links.

Häufig gestellte Fragen

„Wird AbbVie Q2 Global Skyrizi Nettoumsatz über __ liegen?" ist ein Prognosemarkt auf Polymarket mit 5 möglichen Ergebnissen, bei dem Händler Anteile auf Basis ihrer Einschätzung kaufen und verkaufen. Das aktuell führende Ergebnis ist „21 Mrd. $" mit 45%, gefolgt von „18 Mrd. $" mit 28%. Die Preise spiegeln Echtzeit-Wahrscheinlichkeiten der Community wider. Ein Anteilspreis von 45¢ bedeutet, dass der Markt diesem Ergebnis eine Wahrscheinlichkeit von 45% zuweist. Diese Quoten ändern sich laufend, wenn Händler auf neue Entwicklungen reagieren. Anteile am richtigen Ergebnis können bei Marktauflösung für jeweils $1 eingelöst werden.

„Wird AbbVie Q2 Global Skyrizi Nettoumsatz über __ liegen?" ist ein neu erstellter Markt auf Polymarket, gestartet am Jul 18, 2026. Als früher Markt haben Sie die Gelegenheit, zu den ersten Händlern zu gehören, die die Quoten setzen und die ersten Preissignale des Marktes etablieren. Sie können diese Seite auch als Lesezeichen speichern, um Volumen und Handelsaktivität zu verfolgen, während der Markt an Fahrt gewinnt.

Um auf „Wird AbbVie Q2 Global Skyrizi Nettoumsatz über __ liegen?" zu handeln, durchsuchen Sie die 5 verfügbaren Ergebnisse auf dieser Seite. Jedes Ergebnis zeigt einen aktuellen Preis, der die implizierte Wahrscheinlichkeit des Marktes darstellt. Um eine Position einzunehmen, wählen Sie das Ergebnis, das Sie für am wahrscheinlichsten halten, wählen Sie „Ja" um dafür oder „Nein" um dagegen zu handeln, geben Sie Ihren Betrag ein und klicken Sie auf „Handeln". Liegt Ihr gewähltes Ergebnis bei Marktauflösung richtig, zahlen Ihre „Ja"-Anteile jeweils $1 aus. Liegt es falsch, zahlen sie $0. Sie können Ihre Anteile auch jederzeit vor der Auflösung verkaufen.

Der aktuelle Favorit für „Wird AbbVie Q2 Global Skyrizi Nettoumsatz über __ liegen?" ist „21 Mrd. $" mit 45%, was bedeutet, dass der Markt diesem Ergebnis eine Wahrscheinlichkeit von 45% zuweist. Das nächstliegende Ergebnis ist „18 Mrd. $" mit 28%. Diese Quoten werden in Echtzeit aktualisiert, wenn Händler Anteile kaufen und verkaufen. Schauen Sie regelmäßig vorbei oder speichern Sie diese Seite als Lesezeichen.

Die Auflösungsregeln für „Wird AbbVie Q2 Global Skyrizi Nettoumsatz über __ liegen?" definieren genau, was passieren muss, damit jedes Ergebnis als Gewinner erklärt wird – einschließlich der offiziellen Datenquellen zur Bestimmung des Ergebnisses. Sie können die vollständigen Auflösungskriterien im Abschnitt „Regeln" auf dieser Seite über den Kommentaren einsehen. Wir empfehlen, die Regeln vor dem Handeln sorgfältig zu lesen, da sie die genauen Bedingungen, Sonderfälle und Quellen festlegen.